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Is the concept of integrative, preventive and personalised medicine applicable to the relationship between retinitis
pigmentosa (RP) and ocular blood flow (OBF)? RP encompasses a group of hereditary diseases of the posterior
segment of the eye characterised by degeneration, atrophy and finally loss of photoreceptors and retinal pigment
epithelium, leading to progressive visual loss. Many different mutations affecting different genes can lead to the
clinical picture of RP. Even though the disease has a clear genetic background, there are obviously other factors
influencing the manifestation and progression of RP. In this review, we focus on the role of OBF. There is evidence
that, in PR patients, OBF is more reduced than one would expect secondary to the retinal atrophy. The main cause
of this additional component seems to be primary vascular dysregulation (PVD) syndrome. As PVD syndrome is
partly treatable, a vascular evaluation of RP patients is meaningful. Based on the outcome, a targeted individualised,
preventive or supportive treatment might be introduced in selected RP patients.
Keywords: Retinitis pigmentosa, Primary vascular dysregulation syndrome, Ocular blood flow, Endothelin,
Integrative medicine, Predictive, preventive and personalised medicineReview
Introduction
Retinitis pigmentosa (RP) encompasses a large group of
hereditary diseases of the posterior segment of the eye
characterised by degeneration, atrophy and finally loss of
photoreceptors and retinal pigment epithelium (RPE),
leading to progressive visual loss. The term ‘retinitis’
refers to an inflammatory component. Indeed, most dys-
trophic and degenerative diseases are accompanied by
low-grade inflammation. The term ‘pigmentosa’ refers
to the pigmentary changes with a perivascular ‘bone-
spicule’ configuration in the fundus of the eye (Figure 1).
The fact that a number of different mutations affecting
different genes [1] lead to the clinical picture described
phenomenologically as RP explains the heterogeneity of
the phenotypes, including age of onset, rate of progression
and severity of the disease. Even though the disease has a
genetic background, we assume that additional factors
influence the manifestation of the disease. One potential
modifying factor is disturbed ocular blood flow (OBF).
Indeed, reduced OBF in RP patients has been described
[2-4]. Blood flow is more or less always reduced in* Correspondence: kkonieczka@uhbs.ch
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reproduction in any medium, provided the oratrophic tissue, secondary to a decreased demand for
supply. However, in this review, we summarise and focus
on findings indicating an additional primary component
of OBF reduction and explore the potential causes of
such a primary component. Finally, we discuss the po-
tential benefit of a vascular evaluation of RP patients
with regard to prophylactic and supportive treatment in
selected patients.Phenomenology of RP
As mentioned above, RP refers to a group of diseases of
progressive retinal degenerations characterised by loss of
photoreceptors and RPE with corresponding loss of func-
tion. The disease has a hereditary basis. The prevalence
of RP is estimated to be one case among 3,000–5,000
individuals, with a total of about two million affected
persons worldwide [5]. The disease starts typically (but
not always) with night blindness followed by bilateral,
symmetric, progressive concentric constriction of the
visual field (Figures 2 and 3), finally leading to tunnel
vision or even complete blindness. By fundoscopy, the
ophthalmologist finds a bone-spicule retinal pigmentation
starting in the periphery and extending slowly towards the
centre of the retina, attenuated retinal vessels and, in late
stages, a waxy-pale optic nerve head (Figure 4). The elec-
troretinography reveals reduced rod and cone responsesral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Fundus photograph of a patient with retinitis pigmentosa with the typical bone-spicule pigmentary changes (arrows). Left:
photograph; right: fluorescein angiogram.
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finally lacking (Figure 7).
In addition, RP can be accompanied by cataract [6],
open-angle glaucoma, refractive errors [7], keratoconus,
optic nerve head drusen and cystoid macular oedema [8]
(Figure 8).
It should be noted that both the types and the severity
of clinical symptoms and signs, as well as age of onset
and rate of progression, vary markedly among patients
(reviewed in [9]). Symptoms may already start in child-
hood; however, they more often begin in early adulthood
and sometimes in mid-adulthood. Although the progres-
sion of the disease is variable, typically, severe visual im-
pairment occurs most often by the age of about 40–50
years [1].
This large clinical heterogeneity is at least partly
explained by the genetic heterogeneity. However, after a
short summary of the genetics of RP, we will focus our
discussion here mainly on the question of whether
disturbed blood flow may also contribute.Genetics of RP
The condition can be inherited in an autosomal-dominant,
autosomal-recessive or X-linked fashion. Non-Mendelian
inheritance patterns, such as digenic [10] and maternal
(mitochondrial) [11] inheritance, have also been reported.
For the genetics of RP, we refer to a recently published
review [1].
However, the feature shared by all these types of muta-
tions is that they occur in genes coding for proteins
involved in vision, either at the level of rods and cones
or at that of the pigment epithelium (Figure 9). In the
course of the disease, the photoreceptors undergo apop-
tosis [12], which results in reduced outer nuclear layer
thickness of the retina (Figure 10). The pigment depos-
its, also described as bone-spicule pigmentation, result
from both RPE degeneration and RPE migration into theneural retina in response to photoreceptor cells' death
[13] (Figure 1).
The exact mechanism of cell death in RP is not yet
known. There are indications, however, that oxidative
stress is also involved [15]. Any condition that increases
or decreases oxidative stress in the retina is therefore of
interest.RP and ocular blood flow
It is meanwhile well established that OBF in RP patients
is reduced not only in the retina [3] and choroid [4], but
also in the retroocular vessels [2]. The question arises
whether this is only secondary to the retinal atrophy or
whether there is a primary component of OBF dysfunc-
tion (such as an atrophy-independent reduction of OBF)
potentially contributing to the damage. In this context,
two questions are important: (1) At what stage of the
disease does the onset of OBF reduction occur? (2) Is
blood flow reduction confined to the eye?
Interestingly, reduced blood flow velocity in the retina
(increase of the arteriovenous passage time) has been
observed already in the early stages of RP before the
appearance of any ophthalmoscopic signs [16]. With
colour Doppler imaging, Cellini et al. also demonstrated
reduced peak systolic velocities in both ophthalmic ar-
teries and posterior ciliary arteries (Figure 11) (not
explained by the occurrence of other general disorders)
[2]. Furthermore, Cellini et al. also demonstrated that
blood flow disturbance in RP patients was not confined
to the eye, but also occurred in the periphery. With laser
Doppler flowmetry, they demonstrated reduced baseline
peak flow in the cutaneous capillary of the finger and
significantly longer recovery time after cold provocation
[2]. Furthermore, these patients had increased endothelin-
1 (ET-1) plasma levels [2], and ET-1 plasma level corre-
lated with the decrease of peak systolic velocity both in
the ophthalmic artery and in the posterior ciliary arteries
Figure 2 Goldmann visual fields of a RP patient demonstrating progressive concentric constriction. Top: mid-stage RP; bottom: late-stage RP.
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Figure 3 Octopus perimetry demonstrating the extensive visual field loss. Left: mid-stage RP; right: late-stage RP.
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stages of the disease.
Such an increase in ET-1 plasma levels in RP patients
has been described repeatedly [2,17,18] but not con-
firmed by all investigators [19].
It is at present not known why ET-1 levels are
increased at least in some RP patients. Endothelin (ET)
(Figures 12 and 13), identified in 1988 by Yanagisawa
and colleagues [20], is a strong endogenous vasocon-
strictor. Endothelins are a family of 21 amino acid pep-
tides, where the predominant isoform is ET-1. ET-1 is
essentially produced by vascular endothelial cells. How-
ever, more or less, any cell can produce ET-1 if the cell
is under stress. Particularly important is hypoxic stress,
which leads to an increase of HIF-1 alpha and therebyFigure 4 Fundus photograph in patient with late-stage RP
with the classic triad. Bone-spicule retinal pigmentation (black
arrow), retinal vessel attenuation (white arrow) and waxy disc pallor
(red arrow).increased expression of ET-1. Therefore, the observed
increase of plasma level could be secondary to hypoxic
or oxidative stress somewhere in the body. It is at
present unknown whether the ET-1 level in the eye is
even more increased than in the plasma. It is known that
ET-1 can be synthesised and secreted in RPE cells [21].
This locally secreted ET-1 may also play a role in cell
proliferation, migration and repair processes in the ret-
ina. Independent of the cause of the ET-1 increase in the
plasma, this increase reduces OBF, particularly in the
choroid and the optic nerve head [22] and, in high
concentrations, even in the retina [23].The impact of primary vascular dysregulation syndrome
in RP
We hypothesise that primary vascular dysregulation
(PVD) syndrome [24-26] might be a main cause for both
the observed findings in blood flow reduction and the
increase in ET-1.
PVD is a predisposition to react differently to a num-
ber of stimuli like coldness [24,25] and physical or emo-
tional stress. The most prominent sign of PVD is the
dysregulation of vessels, hence the name of the syn-
drome [27]. The most notable sign in the vessels are
vasospasms. This explains why for PVD the term vaso-
spastic syndrome [28] was used in the past.
The main signs and symptoms of PVD are cold hands
and/or feet [25] (Figure 14), particularly when exposed
to cold (Figure 15) or emotional stress and low blood
pressure [29]. Typically, these subjects have mildly
increased ET-1 plasma levels [30]. One cause of the sys-
temic hypotension (Figure 16) observed in these subjects
is the reduction of the reabsorption of sodium in the
proximal tubule of the kidneys [31]. This, in turn, is due
to the increase of prostaglandin E2 (PGE2) by the ET-1.
PVD subjects also often have reduced feelings of thirst
[30], which is also due to the increased ET-1 plasma
levels.
Figure 5 Scotopic electroretinography (ERG), ISCEV standard (International Society for Clinical Electrophysiology of Vision). Normal ERG
responses in healthy subject (left) and extinguished responses in RP patient (right).
Figure 6 Multifocal electroretinogram. Severely attenuated paracentral responses in RP patient (left) in comparison to normal responses in a
healthy subject (right).
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Figure 7 Dark adaptation. Dark adaptation of rods (green line) and cones (red line) in a healthy subject (top) and disturbed dark adaptation
(loss of red-green dissociation) in RP patient (bottom).
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drugs—most probably due to altered expression of ABC-
transport proteins [33]. PVD subjects also require alonger time to fall asleep, especially when they are cold
[34] (as warm feet are generally a prerequisite for falling
asleep). They also suffer more often from headaches and

















Figure 9 Phototransduction in rod photoreceptors. Mutations of genes involved in this process can lead to RP (Adapted from [14] with
permission).
Figure 10 Histological section through the human retina. Left: healthy retina; middle: retina of a patient with mid-stage RP; right: retina of a
patient with late-stage RP.
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Figure 11 Peak systolic velocities (mean ± SEM) in posterior
ciliary arteries. Control subjects (left) and patients with early-stage
RP (right) (based on [2]).
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(ET level influences the threshold of pain sensation).
PVD occurs more often in females [37] and in thin sub-
jects [37-39].
Interestingly, most of these signs and symptoms typ-
ical of PVD subjects also seem to occur more frequently
in RP patients than in unselected controls (Konieczka K
et al., unpublished work). We therefore discuss here the
link between PVD and OBF. PVD syndrome also
includes disturbed autoregulation of ocular perfusion
[40], spatial irregularity of retinal vessels and reduced
neurovascular coupling [41] (Figure 17). Disturbed regu-
lation of OBF leads to unstable blood flow (and there-
fore unstable blood supply), and this, in turn, leads to an
increase in free radicals and chronic oxidative stress.
Indeed, there are many indications that oxidative stress
is increased in PVD [42].Figure 12 Endothelin. ET-1 arises by cleaving the precursor molecules (AdThe high prevalence of PVD in RP patients might
explain the primary component of OBF dysfunction in
RP patients.Therapeutic consequences
Dealing with a severe disease, any treatment ameliorat-
ing this condition would be welcome. On the other
hand, it would be wise to avoid encouraging false hope.
We know from clinical experience that the symptoms of
PVD can be reduced to some extent. If blood pressure is
very low, increased salt intake increases blood pressure
slightly but improves vascular regulation markedly. The
same observation has been made with fludrocortisone
[43]. The other symptoms of dysregulation can be miti-
gated either by magnesium [44] or by a low dose of cal-
cium channel blockers (CCBs) [45] or even omega-3
fatty acids [46,47].
Interestingly, it has been shown that central visual field
defects progress slower in RP patients treated with the
CCB nilvadipine [48]. Furthermore, in a patient with the
clinical picture of RP, without a genetic history but with
chronic hypomagnesaemia, the visual field progression
was stopped after magnesium (a physiological CCB) sub-
stitution [49]. Magnesium and CCBs both have some
neuroprotective effect and improve blood flow regula-
tion. They reduce the vasoconstrictive effect of ET-1
[50,51].
Interestingly, diet rich in omega-3 fatty acids—which
we often use to treat PVD—can also slow mean annual
rates of decline of visual acuity in RP patients receiving











Figure 13 Endothelin receptors. In humans, the effects of ET-1 are mediated by two types of ET receptors: the type-A receptor (ETA) and the
type-B receptor (ETB) (Adapted from [14] with permission).
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deed, oxidative damage is under investigation as a pos-
sible therapeutic target in RP disease [15,53].
As OBF dysfunction, potentially due to PVD syn-
drome, occurs often in RP patients, we consider theFigure 14 Thermography of hands and faces. A subject without PVD (levascular evaluation of such patients meaningful. If
reduced OBF in the context of PVD syndrome is diag-
nosed, a supportive treatment with a diet rich in both
omega-3 fatty acids and antioxidants and with magne-
sium (or, in selected patients, even with low-dose CCBs)ft) and a subject with PVD (right) (Adapted from [32] with permission).
Figure 15 The nailfold capillary microscopy examination. Left: examination setting with cooling device; middle: picture from a video with
normal capillary blood flow; right: picture from the video demonstrating blood flow cessation after cold provocation in a PVD subject (Adapted
from [32] with permission).
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salt intake or, in extreme cases, even low-dose fludrocor-
tisone might be worthwhile. We would like to empha-
sise, however, that such recommendations are mainly
based on clinical experience. Scientific studies are unfor-
tunately, at present, still sparse.
Conclusions
RP is a disease with a clear genetic background. How-
ever, OBF is more reduced in RP than one would expect
secondary to the retinal atrophy. The main cause of this
OBF reduction seems to be PVD syndrome. As PVD
syndrome is partly treatable, an individualised treatment
[54,55] might be introduced in selected RP patients
based on the outcome of a vascular evaluation.
Further studies are recommended to establish the rela-
tionship between reduced OBF and the different stages
of the RP disease and to confirm our hypothesis that the
main cause of this blood flow reduction is the PVD syn-
drome. Furthermore, a more detailed relationship be-
tween the vascular dysfunction and other involved
factors such as ET or nitric oxide should be established.Figure 16 Outcome of blood pressure monitoring. Yellow: normal rangControlled studies evaluating the effect of vascular treat-
ment on visual function will be crucial. While waiting
for the outcomes of such studies, we recommend simple,
not expensive treatments such as magnesium or omega-
3 fatty acids in targeted selective patients [54,55].
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